SML Biopharm, a company specialized in developing mRNA-based therapeutics (CEO Nam Jae-hwan), signed a memorandum of understanding (MOU) for technical cooperation with French biotech Affilogic on the 8th.
This MOU was pursued as part of cooperation to integrate Affilogic’s Nanofitin targeting technology into SML Biopharm’s mRNA-LNP platform. The two companies plan to explore collaboration possibilities for next-generation therapeutic development based on their respective core technologies and jointly discuss ways to create technical synergies.
Based on its in-house mRNA expression platform and lipid nanoparticle (LNP) delivery technology, SML Biopharm is developing therapeutics and vaccines applicable to various fields including infectious diseases, rare diseases, and cancer. The company said it continues to pursue mRNA therapeutic design and formulation development, and is continually seeking ways to improve therapeutic efficacy and safety.
Affilogic is a biotech company headquartered in Nantes, France, that possesses the Nanofitin platform, an antibody-replacement technology. Nanofitins are small, highly stable binding proteins that exhibit high specificity for various biological targets and can readily bind to a range of therapeutic agents such as LNPs, antisense oligonucleotides (ASO), and siRNA to enable delivery to specific cells or organs. Affilogic has built active collaborations with global pharmaceutical companies based on its technological capabilities.
The companies expect that, depending on future research results, this could lead to joint patent applications, technology licensing, or commercialization.
An SML Biopharm official said, “We expect that cooperation with Affilogic will further expand the applicability of mRNA-LNP technology,” adding, “Through this MOU, we will not only secure global-level technology but also create various opportunities for future commercialization.”
SML Biopharm was founded in 2021 by Professor Nam Jae-hwan of the Catholic University and, based on differentiated mRNA technology, develops mRNA vaccines and therapeutics across various fields. It counts Samkwang Medical Foundation, Samkwang Labtree, SML Meditree, and SML Jenitree as affiliated companies under the Samkwang Biotree Group.
Yakup News https://www.yakup.com/news/index.html?mode=view&cat=12&nid=309880 Hit News http://www.hitnews.co.kr/news/articleView.html?idxno=64322 FETV https://www.fetv.co.kr/news/article.html?no=191474 Health In News https://www.healthinnews.co.kr/view.php?ud=2025050816060470356aa9cc43d0_48
